Remdesivir-capsule
Health

Remdesivir first coronavirus drug to receive EU approval 

564

The first drug to treat severe cases of Covid-19 in the European Union has been given the green light, with the European Commission approving remdesivir.

“We will leave no stone unturned in our efforts to secure efficient treatments or vaccine against the coronavirus,” Stella Kyriakides, the EU’s health commissioner, said in a statement.

It is the first time the EU’s executive arm has granted the approval to a Covid-19 drug and was the last step for remdesivir to be given the full the go-ahead.

The US has bought up virtually all the stocks for the next three months of Remdesivir leaving none for the UK, Europe or most of the rest of the world.

 

What we know about Remdesivir

Remdesivir (GS-5734™) is authorized for use under an EUA only for the treatment of patients with suspected or laboratory-confirmed SARS-CoV-2 infection and severe COVID-19. Severe disease is defined as patients with an oxygen saturation (SpO2) ≤94% on room air or requiring supplemental oxygen, mechanical ventilation, and/or extracorporeal membrane oxygenation (ECMO). Remdesivir is authorized for adult or pediatric patients who are admitted to a hospital and for whom use of an IV agent is clinically appropriate. Remdesivir must be administered intravenously.

Remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection, according to clinical trials funded by the National Institute of Allergy and Infectious Diseases and others.

Serious and unexpected adverse events may occur that have not been previously reported with remdesivir use.

Warnings: In clinical studies with remdesivir, infusion-related reactions and liver transaminase elevations have been observed. Remdesivir should not be used in patients who are hypersensitive to any ingredient of remdesivir. If signs and symptoms of a clinically significant infusion reaction occur, immediately discontinue administration of remdesivir and initiate appropriate treatment. Do not initiate remdesivir in patients with ALT ≥5x ULN; discontinue therapy in patients who develop ALT ≥5x ULN or ALT elevation accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or INR.

Patients should have appropriate clinical and laboratory monitoring to aid in early detection of any potential adverse events. Monitor renal and hepatic function prior to initiating and daily during therapy with remdesivir; additionally monitor serum chemistries and hematology daily during therapy. The decision to continue or discontinue remdesivir therapy after development of an adverse event should be made based on the clinical risk/benefit assessment for the individual patient. For additional information and mandatory adverse event reporting, please see the Fact Sheet for Healthcare Providers.

Leave a comment

Related Articles

FG launches free Caesarean section initiative for Nigerian women

The Federal Government has launched a life-changing initiative, providing free Caesarean sections...

Cholera claims 10 lives in Enugu

At least 10 fatalities have been recorded in Enugu State following a...

Mpox outbreak: Cross River, Lagos lead with highest cases

The Nigeria Centre for Disease Control and Prevention (NCDC) says Mpox cases...

NAFDAC seizes N5bln flood-damaged drugs in Borno

The National Agency for Food and Drug Administration and Control (NAFDAC) has...

LUTH starts bone marrow transplant to cure sickle cell disease

The Lagos University Teaching Hospital (LUTH), in conjunction with the Sickle Cell...

Nigeria reports 4,915 suspected meningitis cases, 361 fatalities – NCDC

The Nigeria Centre for Disease Control and Prevention (NCDC) has reported a...

Mpox outbreak: 67 cases confirmed in 23 states – NCDC

The Nigeria Centre for Disease Control and Prevention (NCDC) has confirmed 67...

NAFDAC probes Delta Pastor Jeremiah’s “agency-approved” miracle water, soap

The National Agency for Food and Drug Administration and Control (NAFDAC) has...

FG sets Oct. 8 as the tentative date for mpox vaccination

The National Primary Health Care Development Agency (NPHCDA) has announced that the...

FG grants 50% electricity subsidy to hospitals nationwide

The Federal Government has granted a 50 percent subsidy on electricity consumption...

U.S. donates 10,000 Mpox vaccines to Nigeria

The United States Government on Tuesday donated 10,000 doses of the Jynneos...

Counterfeit beverages: NAFDAC clamps down on Bauchi stores, markets

The Bauchi State Office of the National Agency for Food and Drug...

NAFDAC shuts down bakery for using unfortified sugar, banned potassium bromate

The National Agency for Food and Drug Administration and Control (NAFDAC) has...

Newly inaugurated Lagos private medical facility forays into nuclear medicine

“Nuclear medicine helps in the treatment of thyroid disease, cancer, and arthritis,...

Counterfeit alcoholic beverages: NAFDAC seals 100 shops, suspects apprehended in Enugu

The National Agency for Food Drug Administration and Control (NAFDAC) has shut...

Illicit drugs fuel crimes, criminalities in Nigeria – Marwa

Retired Brig.-Gen. Buba Marwa, the Chairman of the National Drug Law Enforcement...

PCN descends on unlicensed medicine outlets, shuts 531 in Abuja

The Pharmacy Council of Nigeria (PCN) has closed down 531 medicine outlets...

Cholera outbreak: FG in talks with GAVI to secure emergency vaccine doses

Amid a global vaccine shortage, the Federal Government says it has sought...

Housing, transport, economic reforms critical to containing cholera outbreak – FG

The Federal Government has declared that simultaneously addressing the interconnected issues of...

FEC approves $1.4bln to strengthen NDLEA’s fight against drug trafficking

The Federal Executive Council (FEC) has approved N1.99 billion for the purchase...